AstraGenomics is a biotechnology company pioneering innovative genome editing technologies. Powered by a systematic platform integrating computational biology and lab automation, the company has developed a proprietary, diversified tool library for large fragment gene writing and nuclease-based gene editing.

Leveraging our core technologies, we are advancing therapeutic pipelines focused on: in vivo gene integration therapy in the liver for genetic diseases, in vivo CAR-T cell therapy, and in vivo gene knockout therapy for metabolic diseases.

Beyond internal pipeline development, the company actively engages in technology out-licensing and joint product development across multiple industries, including cell and gene therapy, agriculture and CRO/CDMO.

At the BIO International Convention, AstraGenomics is going to present on Monday, June 16 at 2:00PM in Room 153C.